PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.33
D/E ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.07. Howard Marks would check for debt covenant compliance and refinancing risks.
0.93
Exceptionally low net debt at less than half the Medical - Pharmaceuticals median of 2.64. Joel Greenblatt would praise this conservative approach, but verify Operating Margins versus peers.
158.19
Coverage of 158.19 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.
0.67
Current ratio below 50% of Medical - Pharmaceuticals median of 3.01. Michael Burry would check for immediate refinancing needs.
0.19%
Intangibles less than half the Medical - Pharmaceuticals median of 3.31%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.